Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN

Cervical Cancer Clinical Trial

— SUIVICIN  

Official title:

Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04057924
• Other study ID #: CHUBX 2019/03
• Status: Recruiting
• Start date: August 23, 2019
• Est. completion date: September 1, 2029

Study information

• Verified date: December 2023
• Source: University Hospital, Bordeaux
• Contact: Jean-Luc Brun, MD, PhD
• Phone: 335 56 79 59 85
• Email: jean-luc.brun[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old. This follow-up is proposed as an alternative to the treatment of reference (conization) with a possible extension to 4 years

Description:

The INCa recommendations of December 2016 propose the destruction or abstention-monitoring of high-grade histological cervical lesions (HSIL) as an alternative to conization under certain conditions. These are women under 30 years old, with a small lesion in colposcopy, without any sign of invasion, with a squamocolumnar junction seen. These women must accept the principle of regular monitoring by cytology and colposcopy +/- biopsy every 6 months for a maximum of 2 years. HSIL group 2 histological entities CIN2 and CIN3. It is recognized that CIN2 are associated with CIN1 and CIN3 biology whose diagnosis is the result of the subjectivity of colposcopy allowing cervical biopsy and the variability of pathological interpretation due to poor reproducibility of histological diagnosis. CIN2 regress spontaneously in more than 50% of cases at 1 year, either completely (no lesion) or partially (LSIL low grade lesions). No invasive lesions are diagnosed over 2-year observation periods. Among the clinical, pathological and virological criteria, only the initial HPV genotyping seems to have a prognostic influence. There is therefore no strong scientific argument for routine conization in a woman over 30 years of age with a CIN2 lesion extended over more than two quadrants. In addition, conization is associated with an obstetrical risk (prematurity) and post-therapeutic colposcopic cervical stenosis complicates subsequent monitoring in case of abnormal smears. These considerations encourage the extension of the indications of abstention monitoring in the management of women with CIN2 wishing to procreate with an extension of the age to 39 year old, with no limit of size of the lesion and to satisfactory colposcopy

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: September 1, 2029
• Est. primary completion date: September 1, 2029
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• CIN2 confirmed by biopsy, age between 18 and 39 years,

• satisfactory colposcopy identifying the junction and the lesion,

• affiliated person or beneficiary of a social security scheme,

• having given their oral agreement and authorization to the processing of their data.

Exclusion Criteria:

• Pregnancy in progress,

• history of conization,

• atypical or atypical glandular cells or cancer incidentally discovered during smear,

• prophylactic vaccination against HPV,

• active systemic infection requiring treatment, history of HIV infection, congenital or acquired immunodepression,

• long-term treatment with corticosteroids or immunosuppressants, placement under safeguard of justice,

• non-compliance with protocol requirements, in particular a supposed lack of compliance with long-term follow-up

Related Conditions & MeSH terms

• Cervical Cancer
• HPV Infection
• Papillomavirus Infections
• Uterine Cervical Dysplasia
• Uterine Cervical Neoplasms

Intervention

Other:
• abstention from CIN2 treatment and surveillance for at least 2 years
Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years

Locations

Country	Name	City	State
France	CHU Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	rate of spontaneous regression of CIN2 at 2 years	Rate of spontaneous regression of CIN2 at 2 years, either complete (disappearance of the lesion) or partial (	2 years
Secondary	rate of regression of CIN2 at 4 years	rate of regression of CIN2 at 4 years in women who responded to the main rate of regression of CIN2 at 4 years in women who responded to the main objective (disappearance of the lesion or lesions	4 years
Secondary	4-year regression rate of CIN2 that persisted for 2 years	evaluate the 4-year regression rate of CIN2 that persisted for 2 years in women who had not been treated with conization	1, 2, 3 and 4 years
Secondary	HPV viral expression	Binary criteria: yes / No	1, 2, 3 and 4 years